



RHS Limited ACN 010 126 708

ASX Release
5th June 2017

RHS COMPLETES PLACEMENT TO RAISE \$1.5M

Adelaide, 5 June 2017: RHS Limited (ASX: RHS) ("RHS" or "the Company") is pleased to announce that it has completed a placement of 10,714,285 shares to sophisticated investors at \$0.14 per share through Taylor Collison Limited as lead broker. The capital raising of \$1.5M will assist expansion of marketing and business development activities, particularly collaborations for commercial opportunities for DOPlify™ including in liquid biopsy and non-invasive PGS. The \$0.14 share price for the placement is an approximate 8.1% discount to the VWAP of the last 15 days on which trades occurred.

CEO Dr Michelle Fraser commented "After a concerted and focussed effort on product development, RHS has entered into an exciting time of growth and opportunity. Our repositioning as a single cell molecular tools company has been reinforced by the recent change to the Company's name. This new investment provides opportunity to advance key areas of our business that will form the basis for increasing revenues, through both sales of kits and services as well as through furthering commercial relationships".

The placement will utilise available capacity of the Company's issued capital prior to the placement pursuant to ASX Listing Rule 7.1A, and ASX Listing Rule 7.1. Following the issue and allotment of these shares, RHS will have 89.9M shares on issue.

For further information please contact:

Dr Michelle Fraser
CEO and Managing Director
Tel: (+61 8) 8152 9348
michelle.fraser@rhsc.com.au

Dr David Brookes
Chairman
Tel: (+61 8) 8152 9383
david.brookes@rhsc.com.au

About RHS

RHS is a developer of advanced single cell genomic technologies focussed on improving health and research outcomes. With over 10 years of technical experience in the field. RHS' platform whole genome amplification (WGA) kit DOPlify™ has been independently verified as globally competitive and is broadly applicable for DNA analysis; it also forms the basis for the Company's EmbryoCollect™ kit that has been specifically developed for Pre-implantation Genetic Screening (PGS). RHS also utilises these technologies and in-house expertise to provide both microarray and Next Generation Sequencing PGS services.

Reproductive Health Science Ltd.
ACN 010 126 708
ASX: RHS

Issued Capital
79.2 million shares
6.9 million options

Registered Office
Level One, BioSA Incubator,
40-46 West Thebarton Road,
Thebarton, SA 5031

Tel: +61 8 8152 9380
Fax: +61 8 8152 9474

WEB www.rhsc.com.au

Directors
Dr David Brookes (Chairman)
Sue MacLeman
Johnathon Matthews
Dr Michelle Fraser (CEO)

**Finance Officer
& Company Secretary**
Raymond Ridge